https://www.selleckchem.com/mTOR.html
Only 14 patients (1%) tested positive for SARS-CoV-2 during their treatment journey. The majority of 'COVID-altered' management decisions were largely in line with pre-COVID evidence-based guidelines, implying that breast cancer survival outcomes are unlikely to be negatively impacted by the pandemic. However, in this study, the potential impact of delays to BC presentation or diagnosis remains unknown. The majority of 'COVID-altered' management decisions were largely in line with pre-COVID evidence-based guidelines, implying that breast cancer sur
Like
Comment
Share
